Aduro Biotech Inc. (NASDAQ:ADRO) was up 2.4% during mid-day trading on Tuesday . The company traded as high as $14.13 and last traded at $14.07, with a volume of 83,568 shares changing hands. The stock had previously closed at $13.74.

A number of equities research analysts have issued reports on ADRO shares. FBR & Co reissued a “buy” rating and set a $34.00 target price (up previously from $30.00) on shares of Aduro Biotech in a research note on Saturday, May 14th. Leerink Swann reissued a “buy” rating and set a $48.00 target price on shares of Aduro Biotech in a research note on Thursday, May 5th. Canaccord Genuity reissued a “buy” rating and set a $30.00 target price on shares of Aduro Biotech in a research note on Friday, August 5th. Roth Capital reissued a “buy” rating and set a $22.00 target price on shares of Aduro Biotech in a research note on Monday, July 11th. Finally, Zacks Investment Research lowered shares of Aduro Biotech from a “hold” rating to a “sell” rating in a research note on Monday, July 18th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $22.00.

The stock’s 50 day moving average price is $14.50 and its 200 day moving average price is $13.23. The company’s market capitalization is $912.38 million.

Aduro Biotech (NASDAQ:ADRO) last posted its quarterly earnings results on Wednesday, August 3rd. The company reported $0.03 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.21. The business had revenue of $39 million for the quarter, compared to the consensus estimate of $25.24 million. Aduro Biotech’s revenue for the quarter was up 306.3% compared to the same quarter last year. On average, equities research analysts expect that Aduro Biotech Inc. will post ($1.39) earnings per share for the current fiscal year.

In related news, insider Thomas W. Dubensky sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $15.18, for a total transaction of $379,500.00. Following the completion of the sale, the insider now directly owns 12,500 shares of the company’s stock, valued at $189,750. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.